The stock has shown bullish price action recently.

Wall Street’s reaction to the recent secondary offering appears favorable.

A major milestone was achieved when they submitted their CTA for CTX001 in β-thalassemia.

Preclinical data provides rationale for ushering the program forward and their CAR-T efforts should not be overlooked.

Readers who have done their due diligence and are interested in the story should purchase pilot positions in the near term.